Streetbeat News

Regulatory

SYTA

Trading halt status for SYTA was updated at 8:55:00 AM ET. The halt was due to pending news and the resumption times were provided.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 12:55 pm

ADAP

GLPG

The FDA has approved Adaptimmune Therapeutics' (NASDAQ:ADAP) Tecelra for treating unresectable or metastatic synovial sarcoma, marking the first engineered cell therapy for solid tumors in the U.S. and the first new therapy for this rare cancer in over a decade. The approval is based on the SPEARHEAD-1 trial results, showing a 43% overall response rate. Adaptimmune plans to establish multiple treatment centers. Additionally, Adaptimmune has entered a collaboration with Galapagos NV (NASDAQ:GLPG) for future TCR T-cell therapies.

Portfolio Pulse from Vandana Singh

August 02, 2024 | 12:46 pm

LH

Labcorp has received FDA De Novo marketing authorization for its PGDx elio plasma focus Dx, a pan-solid tumor liquid biopsy test. This is the first kitted test of its kind, allowing for tumor mutation profiling from a simple blood draw.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 12:34 pm

INSP

Inspire Medical Systems has received FDA approval for its Inspire V Therapy System, which includes a next-generation neurostimulator and Bluetooth-enabled patient remote and physician programmer. This approval marks a significant advancement in the treatment of obstructive sleep apnea.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 12:07 pm

CVRX

CVRx announced that the Centers for Medicare & Medicaid Services (CMS) has reassigned the Barostim implant procedure to MS-DRG 276 with a national average payment of $43,000 in the FY 2025 Medicare Hospital Inpatient Prospective Payment System. The new payment will be effective starting October 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 12:06 pm

ITRM

Iterum Therapeutics has received a Notice of Allowance from the USPTO for two U.S. patents and has been issued a Canadian patent by CIPO for Sulopenem Etzadroxil and Probenecid (Oral Sulopenem).

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 12:04 pm

A

Agilent Technologies has received FDA approval for its MAGE-A4 IHC 1F9 pharmDx diagnostic tool, which will help identify synovial sarcoma patients eligible for TECELRA TCR T-Cell Therapy.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 12:03 pm

AAPL

AMZN

INTC

META

OXX

QQQ

SPY

Wall Street is set for a downturn as macroeconomic concerns resurface, with the VIX spiking and global markets selling off. Safe-haven gold has reached a record high. Key non-farm payrolls data is awaited, which could significantly impact the market. Tech stocks are expected to be hit hard, with notable premarket movements in Amazon, Apple, and Intel. The semiconductor sector is also under pressure.

Portfolio Pulse from Shanthi Rexaline

August 02, 2024 | 12:01 pm

ALLG

Allego N.V. (NYSE:ALLG) announced its voluntary delisting from the NYSE, with the last trading day expected on August 22, 2024. The company will file a Form 25 with the SEC on August 12, 2024, to initiate the delisting process.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 11:07 am

ADAP

Trading halt status was updated at 7:00:00 AM ET, with a quotation resumption time provided. This update is relevant for investors tracking the affected stocks.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 11:00 am